Willkie advised Clovis Oncology on the deal lovis Oncology, Inc. (NASDAQ:CLVS) announced on April 16 the upsizing and pricing of an underwritten public offering of $300…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
